Pelizaeus-Merzbacher disease …

Neurogenetic Disorders

Updated 11.03.2025
Released 04.07.1995
Expires For CME 11.03.2028

Pelizaeus-Merzbacher disease

Authors: Margie A Ream MD PhD, George Zakhary DO

See Contributor Disclosures

Editor: Andrea Gropman MD

Cite this article

Pelizaeus-Merzbacher disease

In This Article

Quick Link

Introduction

Overview

Pelizaeus-Merzbacher disease (PMD) is an X-linked recessive leukodystrophy caused by pathogenic variants in the proteolipid protein 1 (PLP1) gene, a major component of myelin formation and maintenance. Pelizaeus-Merzbacher disease typically presents in the first year of life with hypotonia, nystagmus, spasticity, and ataxia. There are several forms of Pelizaeus-Merzbacher disease, depending on the type of genetic variant. They range on a clinical spectrum of disease from the severe connatal form to an uncomplicated spastic paraparesis syndrome. In this article, the authors describe the clinical features, pathophysiology, differential diagnosis, diagnostic workup, and management of Pelizaeus-Merzbacher disease and its various forms. Understanding disease pathology and improving the diagnosis rate is increasingly vital as therapeutic options are in development and clinical trials.

Key points

	• Pelizaeus-Merzbacher disease is caused by a variety of pathogenic variants in the PLP1 gene that lead to misfolded or reduced levels of protein, causing oligodendrocyte dysfunction and a reduction or absence of myelin in the central nervous system.
	• The clinical presentation is on a spectrum, from the severe connatal form to an uncomplicated spastic paraparesis syndrome.
	• Common clinical manifestations include nystagmus, hypotonia, ataxia, stridor, and, eventually, spastic paraplegia.
	• As Pelizaeus-Merzbacher disease exhibits X-linked inheritance, males are affected, and females are rarely symptomatic.
	• MRI shows diffuse and symmetric T2 hyperintensity of the white matter in the cerebrum and cerebellum, but diagnosis is confirmed with genetic testing of the PLP1 gene.
	• Treatment is mostly symptomatic, but emerging therapies are being investigated.

Historical note and terminology

Pelizaeus-Merzbacher disease has historically been subdivided into clinical variants based on the age of onset and severity of clinical signs. "Classical" Pelizaeus-Merzbacher disease is the most common presentation and was first described by Dr. Friederich Pelizaeus (46) who discovered the disease after encountering a family of several males with nystagmus, spastic paraparesis, ataxia, and developmental delay. A few years later, Ludwig Merzbacher, a pathologist, described the X-linked recessive inheritance pattern of Pelizaeus-Merzbacher disease (36). The "connatal" form of Pelizaeus-Merzbacher disease was described later and denotes clinically evident onset within the first few weeks of life and a more severe syndrome (52). Seitelberger also described a “transitional” form of Pelizaeus-Merzbacher disease that was intermediate in clinical severity between connatal and classical disease (53). In 1964, Zeman and colleagues pointed out that Pelizaeus-Merzbacher disease is a demyelinating, rather than a demyelinating, entity and stressed the importance of clinical observation and the familial nature of the disorder rather than strict pathological criteria to define the condition (73). They also hypothesized that the defect in Pelizaeus-Merzbacher disease affected a myelin proteolipid. Saugier-Veber and colleagues discovered that some families with X-linked spastic paraparesis have PLP1 variants (50). It must be noted that the phenotypes of Pelizaeus-Merzbacher disease and X-linked spastic paraparesis syndrome overlap.

Clinical manifestations

Presentation and course

	• Pelizaeus-Merzbacher disease has a range of ages of onset, with earlier disease often being more disabling.
	• Pelizaeus-Merzbacher disease can present as nystagmus in the first few months of life, which then often resolves.
	• Spasticity can prevent or cause loss of ambulation.

Clinically, Pelizaeus-Merzbacher disease, caused by duplications in the PLP1 gene, can be classified into three subtypes according to the age of presentation (54): type I, or classic Pelizaeus-Merzbacher disease; type II, or connatal form; and type III, or transitional Pelizaeus-Merzbacher disease (44). Taken together, individuals with duplications present with nystagmus, with or without motor symptoms or seizures, with an average age of symptom onset of 3 months (63). Other disorders can be caused by other types of pathogenic variants in the PLP1 gene, thereby creating a spectrum of PLP1 disorders, including PLP1 null syndrome and spastic paraparesis.

Connatal Pelizaeus-Merzbacher disease. The connatal form is the most severe and presents at birth or within the first few weeks of life with hypotonia, which eventually progresses to spasticity in early childhood. Patients also demonstrate nystagmus, which may have a distinctive rotary component, but horizontal and vertical nystagmus also occur. Abnormal eye movements often dissipate with age. Laryngeal stridor and pharyngeal weakness are common and can lead to respiratory failure (10). Early-onset respiratory insufficiency can be a presenting sign in the connatal form (64). Motor deficits are severe, and it is common for infants to lack head control. Patients do not develop the ability to ambulate or speak, and cognition is significantly impaired. Affected children typically die in infancy or early childhood, usually due to aspiration.

Classic Pelizaeus-Merzbacher disease. Patients with classic Pelizaeus-Merzbacher disease typically present around 1 year of age or within the first few years of life with titubation and initial hypotonia that develops into spasticity starting by 5 years of age. Ataxia and nystagmus are common, and nystagmus can be the initial presenting symptom (08). Fundoscopy shows optic discs that range from pale to frankly atrophic by the age of 6 years due to optic nerve demyelination and atrophy (05). Some patients develop seizures and epilepsy; however, of all the leukodystrophies, Pelizaeus-Merzbacher disease has the lowest incidence of epilepsy at less than 10% (74). Many patients can achieve ambulation with assistive devices, but this is lost in late childhood or early adolescence as spasticity progresses. Apparent disease progression may result from contractures that develop with time. Cognition is typically impaired to some degree, but speech and language often develop. Patients can typically have a lifespan into the fifth or sixth decade (71).

PLP1 null syndrome. Patients initially present with mild spastic quadriparesis that mostly affects the lower extremities; however, symptoms do progress more rapidly than in other forms. Patients with PLP1 null syndrome can have variants preventing expression of PLP due to either a deletion of PLP1, a missense mutation affecting the initiating codon, or a frameshift mutation. They typically develop a complicated spastic paraplegia phenotype that leads to loss of ambulation and impaired cognitive function during late adolescence or early adulthood due to the degeneration of axons (13). These patients also have electrophysiologic evidence for mild, nonuniform demyelinating peripheral neuropathy (55). Nystagmus is not seen in PLP1 null syndrome.

Spastic paraplegia (SPG2). Patients with pure or uncomplicated SPG2 develop spastic paraplegia during childhood. This is likely caused by conservative amino acid substitutions affecting less critical regions of the protein. Patients who do achieve useful independent ambulation, even if for just a few years, would be considered to have spastic paraplegia type 2. Cognition is preserved, and many patients learn to communicate verbally; a few have attended college and held employment. Nystagmus may be present during infancy but is not as consistently seen as in patients with Pelizaeus-Merzbacher disease. Neurogenic bladder symptoms are also common. In addition to the gait and bladder signs, patients with complicated SPG2 may have one or more additional CNS signs, such as cognitive impairment, ataxia, visual impairment, or dysarthria. Gait usually deteriorates during adolescence or early adulthood, and patients typically become wheelchair-dependent during adulthood. Lifespan is normal in both complicated and uncomplicated SPG2 types.

Prognosis and complications

As with most leukodystrophies, the earlier the onset of symptoms, the more severe the disease course. Early-onset severe (connatal) Pelizaeus-Merzbacher disease carries a poor prognosis, with immobility, severe cognitive impairment, and death typically by the end of the second decade. Later-onset (classic) Pelizaeus-Merzbacher disease typically has a better prognosis, with survival into the sixth decade, but it still has similar complications related to its progression to spastic paraplegia. Feeding tubes may be required for children with severe dysphagia and frequent aspiration episodes to minimize episodes of pneumonia as well as to provide nutrition. Constipation and neurogenic bladder are common complications and are likely attributed to the underlying myelination defect, but relative immobility may be contributory. Due to spasticity, patients often progress to develop joint contractures with greater involvement in the legs. Scoliosis, sometimes severe enough to restrict breathing, may develop. Some patients with later onset of disease may be affected more mildly, and a few do not require educational interventions, attend college, and obtain regular employment. This is especially true in spastic paraplegia two or in less severely affected patients with Pelizaeus-Merzbacher disease. In a survey of caregivers of patients with Pelizaeus-Merzbacher disease, the most bothersome symptoms were motor difficulties, communication disorders, constipation, and sleep and mood disorders (40). A natural history study of individuals with PLP1 duplications found that independent ambulation is generally not achieved and that cognition is less severely affected than motor development (63). A functional disability scoring system developed for Pelizaeus-Merzbacher disease can be used to track progression over time (31).

Clinical vignette

A male infant was born at term with unremarkable pregnancy and delivery. Neurologic examination was normal at birth. At around 2 months of age, the infant was noted to have continuous eye movements. He smiled socially but had poor head control at 4 months of age. Motor development was significantly delayed; he rolled over at 15 months and was never able to sit upright without support. He was eventually diagnosed with cerebral palsy. He acquired some speech by 4 years of age but was very dysarthric and qualified for an Individualized Education Program (IEP) at school, including therapy services. He made slow developmental progress, but he was referred to a pediatric neurologist for re-evaluation due to worsening leg spasticity. On exam, he had conjugate eye movements with subtle nystagmus. He had poor head control and truncal titubation. The child could not sit without support or walk and was noted to have significant lower extremity spasticity. Pertinent family history included his mother’s sister, who had a 1-year-old son with nystagmus, hypotonia, and developmental delay. Brain MRI showed diffuse T2 hyperintensity in the cerebral, cerebellar, and brainstem white matter, with typically normal white matter signal on T1-weighted images. Absent central conduction was demonstrated by brainstem auditory evoked response testing, and visual evoked response latencies were very prolonged, although peripheral nerve conduction velocities were normal. The diagnosis of Pelizaeus-Merzbacher disease was made.

Biological basis

	• Pelizaeus-Merzbacher disease is due to a copy number variation or point mutations (missense tends to be more severe) in the PLP1 gene, which resides on the X-chromosome. Segmental duplications of the X-chromosome can cause disease.
	• The PLP1 gene encodes the PLP protein, which is necessary for normal myelin structure.

Etiology and pathogenesis

Genetics. Pelizaeus-Merzbacher disease is caused by pathogenic variants affecting the PLP1 gene, which encodes the PLP protein--a major component of myelin (12; 71). The inheritance pattern is X-linked and is most often recessive, so males are mostly affected. Female heterozygote carriers are almost always asymptomatic or only mildly affected, sometimes with spastic paraparesis. However, codominant expression has been seen in some families with a large number of affected females (21). A case series in Poland demonstrated that in molecularly confirmed patients with Pelizaeus-Merzbacher disease, clinical phenotype can vary in severity, even amongst siblings (37). Although PLP1 point mutations were the first to be shown to cause Pelizaeus-Merzbacher disease (14), it is now clear that segmental X chromosome duplications that span the PLP1 gene are the most common cause of Pelizaeus-Merzbacher disease (58; 39), whereas only 15% to 20% have mutations within the noncoding regions of the gene (18). Triplication and even quintuplication of PLP1 can cause Pelizaeus-Merzbacher disease; however, PLP1 point mutations were associated with more severe disease, whereas PLP1 duplications were associated with milder forms (08). Complete or partial deletion of the PLP1 gene is the least common cause of Pelizaeus-Merzbacher disease. These proportions of mutation types are seen in both familial and sporadic Pelizaeus-Merzbacher disease (39).

Pathophysiology. A great reduction or absence of myelin in the CNS, resulting from variable degrees of oligodendrocyte death or dysfunction caused by PLP1 mutation, is the chief cause of the neurologic disturbances in Pelizaeus-Merzbacher disease (23). Historically, Pelizaeus-Merzbacher disease has also been called a sudanophilic leukodystrophy, as the neutral fat breakdown products of myelin react with Sudan staining (33). Pathologically, patches of demyelination can be found interspaced with perivascular islands of intact myelin and are referred to as myelin islands or tigroid myelination (20; 33).

The PLP1 gene encodes the PLP protein and its alternatively spliced isoform, DM20, which are proteins expressed by oligodendrocytes and are essential for the structure of myelin in the central nervous system (48). Mutations that cause misfolding and prevent plasma membrane incorporation of both PLP and DM20 induce oligodendrocyte apoptosis via elements of the unfolded protein response (59; 22). These mutations are clinically associated with connatal Pelizaeus-Merzbacher disease. Less severe mutations may cause less disruption on oligodendrocyte survival and function. PLP1 duplications cause overexpression of PLP and DM20. PLP overexpression also appears to cause a degree of oligodendrocyte cell death, although the mechanism probably differs from that which causes connatal disease (57). Clear-cut structure-function relationships have not been identified; however, mutations in evolutionarily more highly conserved regions of the protein are associated with more severe clinical disease (07). There is evidence that oligodendrocytes affected by PLP1 mutations demonstrate key hallmarks of ferroptosis, including lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron. Subsequently, iron chelation has been shown to rescue oligodendrocyte apoptosis and enable myelin formation (43).

Patients with the PLP1 gene-null syndrome, caused by mutations that prevent expression of both the PLP1 gene and DM20, develop late-onset neurologic deterioration that usually begins in early adulthood. This deterioration likely results from axonal degeneration and can be inferred by magnetic resonance spectroscopy (13).

Mutations affecting PLP1 can cause axonal degeneration and neuronal loss, particularly in the cerebellum (56). The mechanisms for this neuronal loss are unclear but demonstrate that glial integrity is also important for maintaining neuronal viability.

The disease is usually limited to the CNS, where PLP is the chief protein component of myelin, but peripheral nerve involvement has been found in patients whose mutations prevent full-length PLP1 gene expression (55). Mutations that disrupt the PLP1 gene-specific domain (residues 116 to 150), as well as null mutations, cause mild, demyelinating peripheral neuropathy (55).

Differential diagnosis

Confusing conditions

The differential diagnosis is age-dependent. In the newborn period through infancy, cerebral palsy, spasmus nutans, opsoclonus-myoclonus syndrome, mass lesions, congenital nystagmus, and other leukodystrophies are the chief considerations.

Pelizaeus-Merzbacher-like disease 1 (PMLD1). PMLD1 is caused by mutations in the GJC2 gene. Similar to Pelizaeus-Merzbacher disease, PMLD1 presents in the neonatal period or early infancy with nystagmus and hypotonia that evolves into spasticity during childhood. Patients have delayed acquisition of motor milestones and speech delay due to dysarthria; however, cognition is typically preserved. Cerebellar signs with gait ataxia, dysmetria, and titubation can manifest in childhood. Choreiform movements and dystonia are also common (42). MRI shows diffuse hyperintense T2-weighted signal in the white matter of the cerebrum and cerebellum as well as in the brainstem, with involvement of the corticospinal tracts. Evidence of brainstem involvement on MRI is typically more characteristic of PMLD1 than Pelizaeus-Merzbacher disease (19; 42).

Cerebral palsy. Cerebral palsy, the most common misdiagnosis applied to children with Pelizaeus-Merzbacher disease, must be considered in the differential (03). Titubation and truncal ataxia may be seen in both Pelizaeus-Merzbacher disease and cerebral palsy, but a severely or predominantly ataxic clinical picture argues against a diagnosis of cerebral palsy. Clinical deterioration may occur in patients with Pelizaeus-Merzbacher disease, but cerebral palsy, by definition, cerebral palsy is nonprogressive.

Spasmus nutans. Spasmus nutans consists of a triad of nystagmus, head nodding, and anomalous head positioning without other neurologic abnormalities (29). The nystagmus is either monocular or, when present in both eyes, asymmetric, whereas nystagmus in Pelizaeus-Merzbacher disease is symmetrical.

Other leukodystrophies. The other leukodystrophies differ from Pelizaeus-Merzbacher disease in several ways. Many are demyelinating rather than dysmyelinating disorders and, therefore, often show later onset and more rapid progression, whereas Pelizaeus-Merzbacher disease is usually of early onset and typically stationary or gradually progressive. Exceptions include Canavan disease and Krabbe disease, which can present in the first few months of life, and Aicardi-Goutieres syndrome, which can also be stationary or slowly progressive after an initial period of disease progression. Serum lysosomal enzymes, N-acetylaspartate levels, very long chain fatty acids, organic acids, and urinary sialic acid levels should be measured to rule out Krabbe and Canavan diseases, Tay-Sachs disease, metachromatic leukodystrophy, adrenoleukodystrophy, L-2-hydroxyglutaric aciduria, and Salla disease. Adrenoleukodystrophy usually has a later clinical onset, and MRI scans show occipital white matter changes. Metachromatic leukodystrophy usually presents with frontal white matter changes. Interestingly, although enlargement of the optic nerves is a feature of Krabbe disease, a patient with Pelizaeus-Merzbacher disease with enlarged optic nerves has been described (45). Magnetic resonance spectroscopy in patients with Pelizaeus-Merzbacher disease is normal in most cases, whereas Canavan disease causes greatly elevated N-acetylaspartate levels. Patients with vanishing white matter disease (also known as childhood ataxia with central hypomyelination) often have clinical worsening after febrile illness or traumatic head injury. Except for x-linked adrenoleukodystrophy and Alexander disease, these disorders are autosomal recessive.

X-linked spastic paraplegia. Some cases of X-linked spastic paraplegia are caused by mutations in the PLP1 gene. X-linked spastic paraplegia is typically later in onset than is Pelizaeus-Merzbacher disease, and its signs may be limited to the legs. When the eyes and other parts of the nervous system are involved, there may be no sure way of delineating the conditions; however, abnormal white matter on MRI scans is usually found in cases due to PLP1 gene mutations and should prompt a search for PLP1 mutation. Additionally, adrenal leukodystrophy can present with adrenomyeloneuropathy in affected males, generally in their 20s, and in carrier females over 50 years old. The spinal cord symptoms overlap with those of the genetic spastic paraplegias.

L1 syndrome. Intellectual disability, aphasia, shuffling gait, and adducted thumbs syndrome is linked to Xq28 and is caused by mutations in the L1CAM gene (69). It can present with spastic paraparesis that is like Pelizaeus-Merzbacher disease, but white matter MRI abnormalities are not typically found in this disease.

Cockayne syndrome. Cockayne syndrome should be readily distinguishable because of the beaked nose, large ears, skeletal changes, retinal pigmentation, cataracts, and deafness. It is caused by mutations affecting one of at least two DNA repair enzymes (17). It is sometimes included with the leukodystrophies because of formal similarities of the neuropathological findings with those of Pelizaeus-Merzbacher disease.

Other. Homozygous mutations in the HSPD1 gene that encodes the mitochondrial hsp60 protein can cause early hypotonia, developmental delay, and intellectual disability that progresses to severe spastic quadriparesis. This autosomal recessive syndrome, which is fatal during childhood or adolescence, was identified in an Israeli Bedouin family (34).

Various other genetic mutations can cause Pelizaeus-Merzbacher disease, including mutations in the gap junction C2 (GJC2, formerly GJA12) gene (65). Mutations in RARS cause a hypomyelination disorder akin to Pelizaeus-Merzbacher disease (41). X-linked early-onset hypotonia with nystagmus, developmental delay, and severe intellectual disability with white matter abnormalities on MRI can be caused by mutations in the SLC16A2 (formerly MCT8) gene (67). This syndrome is unusual in that the MRI white matter changes improve over time, even though the clinical syndrome gradually worsens.

Diagnostic workup

	• Diagnosis is often first suspected when hypomyelination is seen on brain MRI.
	• Diagnosis is confirmed by genetic testing showing copy number changes or mutations in the PLP1 gene.

There are no set diagnostic criteria, but a certain constellation of symptoms can be highly suggestive of Pelizaeus-Merzbacher disease. When present, a family history of Pelizaeus-Merzbacher disease, X-linked spastic paraplegia, or "cerebral palsy" is helpful. The individual history of early-onset nystagmus (particularly rotary), respiratory stridor, and the other clinical signs are important, especially in older individuals who may no longer manifest these findings.

Diagnostic imaging and procedures. Magnetic resonance imaging (MRI) is helpful for the diagnosis of Pelizaeus-Merzbacher disease. T2-weighted images will show diffuse and symmetric hyperintense signals in the white matter of the cerebrum, cerebellum, and sometimes brainstem (27). However, this abnormality is in children over about 1 year of age. Myelination is still actively ongoing until much later in life, and MRI is less useful in diagnosing young infants; however, in a normal newborn, there should be myelination in the posterior limb of the internal capsule and brainstem (04). Therefore, with the appropriate clinical syndrome of neonatal nystagmus and hypotonia, lack of myelination in these areas should suggest the diagnosis of Pelizaeus-Merzbacher disease. Brainstem involvement may also indicate PMLD1. At later stages of Pelizaeus-Merzbacher disease, atrophy of the brain is sometimes visible in the scans. Carriers have normal or near-normal MRI scans. CT scans are not useful for diagnosis, although they may show mild signs of brain atrophy. Patients with pure spastic paraplegia 2 may have normal or only mildly abnormal white matter on MRI scans. A myelin scoring system has been used to distinguish subtypes of PLP1-related disease and found that more severe clinical disease is associated with more severe hypomyelination with classic Pelizaeus-Merzbacher disease, demonstrating some slow improvement in myelin over time. In all types, cerebral atrophy can be progressive (15).

Pelizaeus-Merzbacher disease: MRI changes over time

MRI T2 images demonstrating delayed progression of myelination over time in a child with clinical Pelizaeus-Merzbacher disease due to PLP1 missense mutation, most notably in the corpus callosum (star) and posterior lim...

Magnetic resonance spectroscopy may show slight elevation of cerebral white matter N-acetyl aspartate levels (47; 61). Elevation of N-acetyl aspartate levels is characteristic of Canavan disease, but in the absence of macrocephaly, rapid clinical deterioration, and seizures, and with nystagmus and normal urine and serum N-acetyl aspartate, the diagnosis of Pelizaeus-Merzbacher disease should be considered. There are also abnormal phorphorus metabolites (30).

Nerve conduction studies are generally normal, but patients with the PLP1 null syndrome may have mild demyelinating polyneuropathy (55). Evoked potentials, particularly the brainstem auditory and visual evoked potentials, are characteristically abnormal, with delay or disappearance of the central components (35).

Laboratory and genetic testing. When the history and clinical examination indicate a strong possibility of Pelizaeus-Merzbacher disease, genetic testing should be pursued. Because duplications of the PLP1 gene are the most common cause of Pelizaeus-Merzbacher disease, genetic diagnosis usually begins with gene-targeted deletion and duplication analysis. If a duplication is not found, then quantitative polymerase chain reaction (qPCR) testing should be performed to identify patients with duplications too small to resolve by FISH analysis (70). If duplications are excluded, then a search for mutations within the PLP1 gene should be requested. The diagnosis of Pelizaeus-Merzbacher disease is confirmed when a mutation in, or duplication of, the PLP1 gene is found. If the clinical syndrome is consistent with both autosomal recessive inheritance and Pelizaeus-Merzbacher disease, testing for GJC2 (formerly GJA12) mutations should be entertained.

Management

	• Management is symptomatic and should focus on supporting mobility, treating spasticity, and educational supports.
	• Clinical trials of new therapies are underway.

Symptomatic treatment. Management varies with the age of the patient and is largely symptomatic. Periodic evaluations by developmental pediatricians and physiatrists are important for developmental monitoring and managing complications of disease progression, such as contractures or scoliosis. These complications may be improved with physical therapy and antispasticity medications, such as baclofen or botulinum toxin injections. Swallowing and speech therapy should be initiated as needed, and severe feeding and respiratory difficulties may necessitate gastrostomy tube feeding or tracheostomy, respectively. Active respiratory care and monitoring is recommended, as respiratory complications can worsen with increased incidence of unrecognized aspiration pneumonia and recurrent respiratory infections secondary to neuromuscular weakness (28). The use of stool softeners, mild laxatives, and enemas may be required for bowel management. Antiepileptic medications should be considered for the management of seizures. General guidelines for managing patients with leukodystrophies are available (66; 01; 26). Genetic counseling should be offered to affected families. Prenatal and preimplantation genetic testing are available in mutation-confirmed cases (11; 68).

Disease-modifying therapies. There are no approved medications for the direct treatment of Pelizaeus-Merzbacher disease; however, strategies to reduce overexpression of PLP1 and reduce endoplasmic reticulum stress are being evaluated (02; 09). As Pelizaeus-Merzbacher disease can result from the overexpression of the PLP1 gene, it may be a suitable candidate for treatment with emerging antisense oligonucleotides and microRNA therapies, which can lead to the downregulation of overexpressed genes (06).

RNA interference through adeno-associated virus-mediated gene specific suppression against oligodendrocyte-specific PLP1 gene was demonstrated to preserve mature oligodendrocytes from degradation and restored myelin structure in mice (32).

Umbilical cord blood stem cells can be induced to differentiate into oligodendrocytes, and a clinical study (NCT02254863) that includes Pelizaeus-Merzbacher disease is evaluating the effect of intravenous umbilical cord blood transplant and intrathecal administration of umbilical cord blood-derived oligodendrocytes. Another phase 2 clinical study is evaluating the safety, pharmacokinetics, and pharmacodynamics of a novel intrathecally administered antisense oligonucleotide (ION356) seeking to reduce expression of PLP1. More information can be accessed at the following website:NCT06150716.

There has also been research involving dietary interventions. As cholesterol availability is the rate-limiting factor of central nervous system myelin synthesis, mice with PLP1 overexpression fed cholesterol-enriched diets were found to have restoration of oligodendrocyte numbers as well as myelin expression (49). A follow-up study demonstrated that a high fat/low carbohydrate diet can restore oligodendrocyte integrity and increase CNS myelination, suggesting that a ketogenic diet is a potential therapy in Pelizaeus-Merzbacher disease (60).

Investigators found that PLP1 mutations lead to iron-induced cell death through lipid peroxidation, abnormal iron metabolism, and hypersensitivity to free iron (43). Iron chelation rescued oligodendrocytes from cell death, thus, suggesting a therapeutic approach to the disease in the preclinical stage. Mice that overexpress PLP1 develop cerebral inflammation that is ameliorated when the immune system is genetically ablated (24). If a similar inflammatory response occurs in humans, anti-inflammatory treatments might be of therapeutic benefit in patients with Pelizaeus-Merzbacher disease. A study of curcumin to reduce endoplasmic reticulum stress found no benefit (72).

References

01: Adang LA, Sherbini O, Ball L, et al. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Mol Genet Metab 2017;122(1-2):18-32.** PMID 28863857
02: Amanat M, Nemeth CL, Fine AS, Leung DG, Fatemi A. Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on pediatric neurology. Pharmaceutics 2022;14(11):2389. PMID 36365206
03: Barabas G, Taft LT. The early signs and differential diagnosis of cerebral palsy. Pediatr Ann 1986;15:205-14. PMID 3960607
04: Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelination. J Inherit Metab Dis 2005;28:311-43. PMID 15868466
05: Boulloche J, Aicardi J. Pelizaeus-Merzbacher disease: clinical and nosological study. J Child Neurol 1986;1:233-9. PMID 3598129
06: Bradbury AM, Ream MA. Recent advancements in the diagnosis and treatment of leukodystrophies. Semin Pediatr Neurol 2021;37:100876. PMID 33892849
07: Cailloux F, Gauthier-Barichard F, Mimault C, et al. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. Eur J Hum Genet 2000;8:837-45. PMID 11093273
08: Duan R, Ji H, Yan H, et al. Genotype-phenotype correlation and natural history analyses in a Chinese cohort with pelizaeus-merzbacher disease. Orphanet J Rare Dis 2022;17(1):137. PMID 35346287
09: Elitt MS, Tesar PJ. Pelizaeus-Merzbacher disease: on the cusp of myelin medicine. Trends Mol Med 2024;30(5):459-70. PMID 38582621
10: Feldman JI, Kearns DB, Seid AB, Pransky SM, Jones MC. The otolaryngologic manifestations of Pelizaeus-Merzbacher disease. Arch Otolaryngol Head Neck Surg 1990;116:613-6. PMID 2328119
11: Garbern J, Hobson G. Prenatal diagnosis of Pelizaeus-Merzbacher disease. Prenat Diagn 2002;22:1033-5. PMID 12424770
12: Garbern JY. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci 2007;64(1):50-65. PMID 17115121
13: Garbern JY, Yool DA, Moore GJ, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002;125:551-61. PMID 11872612
14: Gencic S, Abuelo D, Ambler M, Hudson LD. Pelizaeus-Merzbacher disease: an X-linked neurologic disorder of myelin metabolism with a novel mutation in the gene encoding proteolipid protein. Am J Hum Genet 1989;45:435-42. PMID 2773936
15: Harting I, Garbade SF, Rosendaal SD, et al. Identification of PMD subgroups using a myelination score for PMD. Eur J Paediatr Neurol 2022;41:71-9. PMID 36368233
16: Heim P, Claussen M, Hoffmann B, et al. Leukodystrophy incidence in Germany. Am J Med Gen 1997;71(4):475-8. PMID 9286459
17: Henning KA, Li L, Iyer N, et al. The Cockayne syndrome group A gene encodes a WD repeat protein that interacts with CSB protein and a subunit of RNA polymerase II TFIIH. Cell 1995;82:555-64. PMID 7664335
18: Hobson GM, Davis AP, Stowell NC, et al. Mutations in noncoding regions of the proteolipid protein gene in Pelizaeus-Merzbacher disease. Neurology 2000;55:1089-96. PMID 11071483
19: Hobson GM, Garbern JY. Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders. Semin Neurol 2012;32(1):62-7. PMID 22422208
20: Hodes ME, Zimmerman AW, Aydanian A, et al. Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2). Am J Med Genet 1999;82:132-9. PMID 9934976
21: Hurst S, Garbern J, Trepanier A, Gow A. Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease. Genet Med 2006;8:371-8. PMID 16778599
22: Inoue K. Cellular pathology of Pelizaeus-Merzbacher disease involving chaperones associated with endoplasmic reticulum stress. Front Mol Biosci 2017;4:7. PMID 28286750
23: Inoue K. Pelizaeus-Merzbacher Disease: Molecular and cellular pathologies and associated phenotypes. Adv Exp Med Biol 2019;1190:201-16. PMID 31760646
24: Ip CW, Kroner A, Bendszus M, et al. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J Neurosci 2006;26:8206-16. PMID 16885234
25: Kapoor R, Zavala AM, Van Meter A, Williams UU, Porche VH, Owusu-Agyemang P. Anesthetic challenges and successful management of a child with Pelizaeus-Merzbacher disease using general and caudal anesthesia. J Anaesthesiol Clin Pharmacol 2018;34(2):250-1. PMID 30104840
26: Keller SR, Mallack EJ, Rubin JP, et al. Practical approaches and knowledge gaps in the care for children with leukodystrophies. J Child Neurol 2021;36(1):65-78. PMID 32875938
27: Kendall BE. Inborn errors and demyelination: MRI and the diagnosis of white matter disease. J Inherit Metab Dis 1993;16:771-86. PMID 8412020
28: Khan SA, Lamar N, Shrestha I, Bhagat S. Diagnosing and managing Pelizaeus-Merzbacher disease: A pediatric struggle. Clin Case Rep 2025;13(10):e71153. PMID 41049215
29: King RA, Nelson LB, Wagner RS. Spasmus nutans: a benign clinical entity. Arch Opthalmol 1986;104:1501-4. PMID 3767683
30: Laukka JJ, Kain KM, Rathnam AS, et al. Altered high-energy phosphate and membrane metabolism in Pelizaeus-Merzbacher disease using phosphorus magnetic resonance spectroscopy. Brain Commun 2022;4(4):fcac202. PMID 36003325
31: Laukka JJ, Stanley JA, Garbern JY, et al. Neuroradiologic correlates of clinical disability and progression in the X-Linked leukodystrophy Pelizaeus-Merzbacher disease. J Neurol Sci 2013;335(0):75-81. PMID 24139698
32: Li H, Okada H, Suzuki S, et al. Gene suppressing therapy for Pelizaeus-Merzbacher disease using artificial microRNA. JCI Insight 2019;4(10). PMID 31092737
33: Maertens P, Dyken PR. Storage diseases: neuronal ceroid‐lipofuscinoses, lipidoses, glycogenoses, and leukodystrophies. In: Goetz CG, editor. Textbook of clinical neurology. Third edition. Saunders, 2007:613-39.
34: Magen D, Georgopoulos C, Bross P, et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am J Hum Genet 2008;83:30-42. PMID 18571143
35: Markand ON, Garg BP, DeMyer WE, Warren C, Worth RM. Brain stem auditory, visual and somatosensory evoked potentials in leukodystrophies. Electroencephalogr Clin Neurophysiol 1982;54:39-48. PMID 6177516
36: Merzbacher L. Eine eigenartige familiar-heriditare Erkrankungsform (Aplasia axialis extracorticalis congenita). Z Gesamte Neurol Psychiatr 1910;3:1-138.
37: Mierzewska H, Jamroz E, Mazurczak T, Hoffman-Zacharska D, Szczepanik E. Pelizaeus-Merzbacher disease in patients with molecularly confirmed diagnosis. Folia Neuropathol 2016;54:59-65. PMID 27179222
38: Mimault C, Cailloux F, Giraud G, Dastugue B, Boespflug-Tanguy O. Dinucleotide repeat polymorphism in the proteolipoprotein (PLP) gene. Hum Genet 1995;96:236. PMID 7635479
39: Mimault C, Giraud G, Courtois V, et al. Proteolipid protein gene analysis in 82 patients with sporadic Pelizaeus-Merzbacher disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. Am J Hum Genet 1999;65:360-9. PMID 10417279
40: Moore KM, Wolf NI, Hobson G, et al. Pelizaeus-Merzbacher disease: a caregiver assessment of disease impact. J Child Neurol 2023;38(1-2):78-84.** PMID 36744386
41: Nafisinia M, Sobreira N, Riley L, et al. Mutations in RARS cause a hypomyelination disorder akin to Pelizaeus-Merzbacher disease. Eur J Hum Genet 2017;25(10):1134-41. PMID 28905880
42: Nahhas N, Conant A, Orthmann-Murphy J, Vanderver A, Hobson G. Pelizaeus-Merzbacher-like disease 1. In: Adam MP, Everman DB, MIrzaa GM, et al, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle, 2022.
43: Nobuta H, Yang N, Ng YH, et al. Oligodendrocyte death in Pelizaeus-Merzbacher disease is rescued by iron chelation. Cell Stem Cell 2019;25(4):531-41. PMID 31585094
44: Osorio MJ, Goldman SA. Neurogenetics of Pelizaeus-Merzbacher disease. Handb Clin Neurol 2018;148:701-22.** PMID 29478609
45: Pavlidou E, Ramachandran V, Govender V, et al. A novel PLP1 mutation associated with optic nerve enlargement in two siblings with Pelizaeus-Merzbacher disease: A new MRI finding. Brain Dev 2017;39(3):271-4. PMID 27793435
46: Pelizaeus F. Uber eine eigenthümliche Form spastischer Lahmung mit Cerebralerscheinungen auf hereditarer Grundlage (multiple Sklerose). Arch Psychiatr Nervenkr 1885;16:698-710.
47: Pizzini F, Fatemi AS, Barker PB, et al. Proton MR spectroscopic imaging in Pelizaeus-Merzbacher disease. AJNR Am J Neuroradiol 2003;24(8):1683-9. PMID 13679292
48: Rasband MN, Macklin WB. Myelin structure and biochemistry. In: Brady ST, Siegel G, Albers RW, Price DL, editors. Basic neurochemistry. Eighth edition. Academic Press, 2012:180-99.
49: Saher G, Rudolphi F, Corthals K, et al. Therapy of Pelizaeus-Merzbacher disease in mice by feeding a cholesterol-enriched diet. Nat Med 2012;18(7). PMID 22706386
50: Saugier-Veber P, Munnich A, Bonneau D, et al. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet 1994;6:257-62. PMID 8012387
51: Seeman P, Krsck P, Namestkova K, Malikova M, Belsan T, Proskova M. Pelizaeus-Merzbacher's Disease (PMD): detection of the most frequent mutation of the Proteolipid protein gene in Czech patients and families with the classical form of PMD. Ceska Slovenska Neurol Neurochir 2003;66(99):95-104.
52: Seitelberger F. Die Pelizaeus-Merzbachersche Krankheit, Klinisch-anatomische Untersuchungen zum Problem ihrer Stellung unter den diffusen Sklerosen. Wien Z Nervenheilkd 1954;9:228-89.
53: Seitelberger F. Pelizaeus-Merzbacher disease. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: Elsevier Science, 1970:150-202.
54: Seitelberger F. Neuropathology and genetics of Pelizaeus-Merzbacher disease. Brain Pathol 1995;5(3):267-73. PMID 8520726
55: Shy ME, Hobson G, Jain M, et al. Schwann cell expression of PLP1 but not DM20 is necessary to prevent neuropathy. Ann Neurol 2003;53:354-65. PMID 12601703
56: Sima AA, Pierson CR, Woltjer RL, et al. Neuronal loss in Pelizaeus-Merzbacher disease differs in various mutations of the proteolipid protein 1. Acta Neuropathol 2009;118(4):531-9. PMID 19562355
57: Simons M, Kramer EM, Macchi P, et al. Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J Cell Biol 2002;157:327-36. PMID 11956232
58: Sistermans EA, de Coo RF, De Wijs IJ, Van Oost BA. Duplication of the proteolipid protein gene is the major cause of Pelizaeus-Merzbacher disease. Neurology 1998;50:1749-54. PMID 9633722
59: Southwood C, Garbern J, Jiang W, Gow A. The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 2002;36:585-96. PMID 12441049
60: Stumpf SK, Berghoff SA, Trevisiol A, et al. Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus-Merzbacher disease. Acta Neuropathol 2019;138(4):147-61. PMID 31482207
61: Takanashi J, Inoue K, Tomita M, et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002;58:237-41. PMID 11805250
62: Tobias JD. Anaesthetic considerations for the child with leukodystrophy. Can J Anaesth 1992;39:394-7. PMID 1563064
63: Trepanier AM, Aguilar S, Kamholz J, Laukka JJ. The natural history of Pelizaeus-Merzbacher disease caused by PLP1 duplication: a multiyear case series. Clin Case Rep 2023;11(9):e7814.** PMID 37636890
64: Ueda A, Shimbo H, Yada Y, Koike Y, Yamagata T, Osaka H. Pelizaeus-Merzbacher disease can be a differential diagnosis in males presenting with severe neonatal respiratory distress and hypotonia. Hum Genome Var 2018;5:18013. PMID 29619238
65: Uhlenberg B, Schuelke M, Rüschendorf F, et al. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet 2004;75:251-60. PMID 15192806
66: Van Haren K, Bonkowsky JL, Bernard G, et al. Consensus statement on preventive and symptomatic care of leukodystrophy patients. Mol Genet Metab 2015;114(4):516-26. PMID 25577286
67: Vaurs-Barriere C, Deville M, Sarret C, et al. Pelizaeus-Merzbacher-like disease presentation of MCT8 mutated male subjects. Ann Neurol 2009;65:114-8. PMID 19194886
68: Verlinsky Y, Rechitsky S, Laziuk K, Librach C, Genovese R, Kuliev A. Preimplantation genetic diagnosis for Pelizaeus-Merzbacher disease with testing for age-related aneuploidies. Reprod Biomed Online 2006;12:83-8. PMID 16454941
69: Vits L, Van Camp G, Coucke P, et al. MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM. Nat Genet 1994;7:408-13. PMID 7920660
70: Wolf NI, Sistermans EA, Cundall M, et al. Three or more copies of the proteolipid protein gene PLP1 cause severe Pelizaeus-Merzbacher disease. Brain 2005;128:743-51. PMID 15689360
71: Wolf NI, van Spaendonk RML, Hobson GM, et al. PLP1 disorders. In: Adam MP, Mirzaa GM, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Accessed 2022.
72: Yamamoto A, Shimizu-Motohashi Y, Ishiyama A, et al. An open-label administration of bioavailable-form curcumin in patients with Pelizaeus-Merzbacher disease. Pediatr Neurol 2024;151:80-3. PMID 38134864
73: Zeman W, DeMyer W, Falls JS. Pelizaeus-Merzbacher disease: a study in nosology. J Neuropathol Exp Neurol 1964;23:334-54. PMID 14137679
74: Zhang J, Ban T, Zhou L, et al. Epilepsy in children with leukodystrophies. J Neurol 2020;267(9):2612-8. PMID 32388833

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Margie A Ream MD PhD

Dr. Ream of Ohio State University College of Medicine received consulting fees from Ionis Pharmaceuticals, Inc.
See Profile
George Zakhary DO

Dr. Zakhary of Nationwide Children's Hospital has no relevant financial relationships to disclose.
See Profile

Editor

Andrea Gropman MD

Dr. Gropman of St. Jude Children's Research Hospital has no relevant financial relationships to disclose.
See Profile

Former Authors

M E Hodes MD PhD
James Garbern MD PhD
Raphael Schiffmann MD
Alexandra Sankovic MD
Erika Fullwood Augustine MD MS

Patient Profile

Age range of presentation: Connatal form: birth to first few months of age

Classical form: first few months to 5 years of age

SPG2: first few months to 5 years of age

PLP1 null syndrome: first few months to 5 years of age
Sex preponderance: Males are predominantly affected. Heterozygote females may demonstrate mild disease.
Heredity: X-linked
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Pelizaeus-Merzbacher disease: E75.27

Hereditary spastic paraplegia: G11.4
ICD-11: Pelizaeus-Merzbacher disease: 8A44.0

Hereditary spastic paraplegia: 8B44.0
OMIM: Pelizaeus-Merzbacher disease: #312080

Acute infantile Pelizaeus-Merzbacher disease: %260600

Autosomal dominant Pelizaeus-Merzbacher disease: #169500

Spastic paraplegia, X-linked (SPG2): #312920

Nystagmus, X-linked: #310700

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Pelizaeus-Merzbacher disease

Differential Diagnosis

cerebral palsy
spasmus nutans
opsoclonus-myoclonus syndrome
mass lesions
congenital nystagmus
- other leukodystrophies
- PMLD1
- X-linked spastic paraplegia
- L1 syndrome
- Cockayne syndrome
- genetic mutations

Also Relevant

Adrenoleukodystrophy
Ataxia
Cockayne syndrome
Globoid cell leukodystrophy
Horizontal gaze palsy
- Intellectual disability
- Transverse myelitis

	• Pelizaeus-Merzbacher disease can occur in any ethnicity.
	• Incidence is difficult to determine but is between 1 in 90,000 and 1 in 770,000 births.

Pelizaeus-Merzbacher disease

Cite this article

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Cockayne syndrome

GM2 gangliosidoses

Levacetylleucine

HHH syndrome

Hyperargininemia

Carbamoyl phosphate synthetase 1 deficiency

Citrullinemias types 1 and 2

Ornithine transcarbamylase deficiency

This is an article preview.
Start a Free Account
to access the full version.